JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258574

Human PDE3B knockout MCF7 cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

PDE3B KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1 and 5 bp deletion in exon1.

View Alternative Names

5''-cyclic phosphodiesterase B, AI847709, Adipocyte cAMP phosphodiesterase cGMP inhibited, CGI-PDE B, CGIP1, CGIPDE1, CGMP inhibited cAMP phophodiesterase, Cyclic GMP-inhibited phosphodiesterase B, Cyclic nucleotide phosphodiesterase, HcGIP1, HcGIP1, rat, homolog of, PDE3B_HUMAN, Phosphodiesterase 3B, Phosphodiesterase 3B cGMP inhibited, cAMP Phosphodiesterase, adipocyte, cGMP-inhibited, cGMP inhibited 3 5 cyclic phosphodiesterase B, cGMP-inhibited 3''

2 Images
Sanger Sequencing - Human PDE3B knockout MCF7 cell lysate (AB258574)
  • Sanger seq

Unknown

Sanger Sequencing - Human PDE3B knockout MCF7 cell lysate (AB258574)

Allele-1 : 5 bp deletion in exon1

Sanger Sequencing - Human PDE3B knockout MCF7 cell lysate (AB258574)
  • Sanger seq

Unknown

Sanger Sequencing - Human PDE3B knockout MCF7 cell lysate (AB258574)

Allele-2 : 1 bp insertion in exon1

Key facts

Cell type

MCF7

Species or organism

Human

Tissue

Breast

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1 and 5 bp deletion in exon1.

Disease

Adenocarcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258574-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human wild-type MCF7 cell lysate", "number":"AB258574-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human PDE3B knockout MCF7 cell lysate", "number":"AB258574-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
PDE3B
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PDE3B also known as cGMP-inhibited phosphodiesterase B is an enzyme with a role in cyclic nucleotide signaling. It possesses a molecular mass of approximately 133 kDa. PDE3B predominantly gets expressed in adipose tissue liver and to some extent in the heart. It breaks down cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) which play key roles in cellular signaling. By hydrolyzing these cyclic nucleotides into their non-cyclic forms PDE3B regulates intracellular levels of these molecules.
Biological function summary

In adipose tissue and liver PDE3B modulates lipogenesis and lipolysis which are vital processes for energy balance. This enzyme interacts with signaling pathways that involve protein kinase A (PKA) and insulin signaling. PDE3B operates as part of larger protein complexes and influences the metabolic rate by regulating the availability of the cAMP for phosphorylation reactions. The activity of PDE3B links closely to the control of energy homeostasis due to its regulatory function on lipid metabolism.

Pathways

PDE3B is integral to the insulin signaling pathway and adiponectin signaling pathway both important in glucose and lipid homeostasis. Within these pathways it functions alongside proteins like AKT and PKA where its activity modulates their signaling efficiency. By controlling the balance of cAMP PDE3B influences signaling cascades that are important for the adaptive cellular responses to hormones and nutrients.

PDE3B connects to conditions such as obesity and type 2 diabetes due to its involvement in energy homeostasis and lipid metabolism. In type 2 diabetes the dysregulation of PDE3B activity affects insulin signaling and glucose uptake. Additionally in the context of obesity PDE3B activity shifts the balance of lipolysis and lipogenesis influencing adipose tissue mass and function. Proteins such as insulin receptors and PKA become closely tied to PDE3B in these disorders highlighting its role in metabolic disease mechanisms.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com